W. Duncan et al., ADVERSE EFFECT OF TREATMENT GAPS IN THE OUTCOME OF RADIOTHERAPY FOR LARYNGEAL-CANCER, Radiotherapy and oncology, 41(3), 1996, pp. 203-207
Citations number
18
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Background and purpose: A correlation has been demonstrated between un
planned prolongation of radiotherapy and increased local relapse. This
review was performed to assess the importance of overall time on the
outcome of curative radiotherapy of larynx cancer. Materials and metho
ds: Retrospective analysis was performed of 383 patients with laryngea
l cancer managed by elective radiotherapy between 1976-1988 in the Dep
artment of Clinical Oncology, University of Edinburgh, Western General
Hospital, Edinburgh. All cancers were confirmed histologically to be
squamous cell carcinomas. All subjects received radiotherapy in 20 dai
ly fractions (except Saturdays and Sundays), employing individual beam
direction techniques and computer dose distribution calculations. Mai
n outcome measures were complete resolution of the cancer in the irrad
iated volume; local relapse; survival and cause-specific survival rate
s. Results: Radiotherapy was completed without any unplanned interrupt
ion (28+/-2 days) in 230/383 (60%) of patients. A statistically signif
icant two-fold increase in local relapse rates was observed when treat
ment was given in 31 days or more. There also was a statistically sign
ificant four-fold increase in laryngeal cancer deaths when the treatme
nt time exceeded 30 days. Conclusions: In patients with laryngeal canc
er, accelerated repopulation of cancer cells probably occurs after the
start of radiotherapy. when the overall treatment time is 4 weeks or
less, gaps at weekends are not detrimental. However, long holiday peri
ods or gaps in treatment longer than 4 days increase the risk of laryn
geal cancer relapse and cancer-related mortality: Significant gaps in
treatment should be avoided. If treatment has to be prolonged, additio
nal radiation dose should be prescribed to compensate for increased tu
mour cell proliferation.